Sunday, October 25, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 26, 2025

Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways

View original at finance.yahoo.com
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways MEDVI Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists Compounded Options Alongside New FDA-Approved Oral Pathway Los Angel…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Payment does not guarantee the writing or dispensing of a prescription

    80% confidence

  • The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed

    80% confidence

  • OASIS 4 trial showed approximately 13-14% average weight loss over 64 weeks with oral Wegovy, with up to 16.6% among adherent participants

    80% confidence

  • Compounded semaglutide in multi-dose vials can create dosing confusion, especially when instructions use 'units' rather than mg/mL measurements, leading to overdoses in some reported cases

    80% confidence

  • MEDVi-affiliated medical professional entities are not contracted healthcare providers with any health insurance plans

    80% confidence

  • STEP 1 trial demonstrated 14.9% average body weight loss over 68 weeks with Wegovy injection

    80% confidence

  • FDA received reports of adverse events including hospitalizations that may be related to dosing errors with compounded semaglutide products

    80% confidence

  • FDA is not aware of a basis for compounding using salt forms such as semaglutide sodium or semaglutide acetate

    80% confidence

  • Novo Nordisk plans a full U.S. launch of oral Wegovy in early January 2026

    80% confidence

  • Limited-time savings offer for oral Wegovy starting dose at approximately $149 per month

    80% confidence

  • Limited-time cash-pay savings offer for Wegovy injection at $199 for initial doses, then $349 thereafter

    80% confidence

  • MEDVi does not provide any Healthcare Services through the Platform and is not licensed to practice medicine

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise Software Races to Govern and Consolidate Around Agentic AI
Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways — Source | Via News | ViaNews Market